With reference to its letter dated 03rd December, 2024, wherein it was, informed that the Company, had received Show Cause Notice (SCN) on 02nd December, 2024 from the Goods and Service Tax (GST) Authority on account of various issues like excess claim of ITC, GSTR9C issue, etc. Further to the aforesaid, Indoco Remedies has informed that the said SCN was duly replied by the Company and the Deputy Commissioner (ST) STU-2 Malkajgiri Division Hyderabad Commercial Tax department Telangana vide its Order dated 24th February, 2025 has dropped the proceeding against the Company under the said SCN. The relevant details as per the requirement of Regulation 30 of the Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, amended from time to time is enclosed in ‘Annexure - A’.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: